<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982289</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1830-MG-201</org_study_id>
    <nct_id>NCT04982289</nct_id>
  </id_info>
  <brief_title>Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis</brief_title>
  <official_title>A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALXN1830 Administered Subcutaneously in Adult Patients With Generalized Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics&#xD;
      (PD), immunogenicity, and efficacy of subcutaneous (SC) ALXN1830 in adults with generalized&#xD;
      myasthenia gravis (gMG).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants have the option to enroll in an Open-label Extension (OLE) Period to receive&#xD;
      ALXN1830 up to 58 weeks (including follow-up period).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Program is undergoing further evaluation.&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) And Serious Adverse Events (SAEs) Up To Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs And SAEs Up To Week 82</measure>
    <time_frame>Up to Week 82 (OLE)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline In Serum Total Immunoglobulin G (IgG)</measure>
    <time_frame>Up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Myasthenia Gravis Activities Of Daily Living Profile (MG-ADL) Total Score</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Quantitative Myasthenia Gravis (QMG) Score</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants With At Least A 2-point Improvement In The MG-ADL Score Over 4 Consecutive Weeks</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants With At Least A 3-point Improvement In The QMG Score Over 4 Consecutive Weeks</measure>
    <time_frame>Up to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Neurological Disorders Fatigue Questionnaire (Neuro-Qol) Fatigue Score</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Trough Concentrations Of ALXN1830</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In IgG Subtypes</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Anti-drug Antibodies (ADA) And Neutralizing Antibodies (Nab) Against ALXN1830</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers Of ADA And Nab Against ALXN1830</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Generalized Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>ALXN1830 Dosing Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALXN1830 Dosing Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALXN1830 Dosing Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo for 8 weeks, then ALXN1830 for 8 weeks, followed by an Observation Period (no treatment) for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1830</intervention_name>
    <description>Administered as an SC infusion.</description>
    <arm_group_label>ALXN1830 Dosing Arm 1</arm_group_label>
    <arm_group_label>ALXN1830 Dosing Arm 2</arm_group_label>
    <arm_group_label>ALXN1830 Dosing Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as an SC infusion.</description>
    <arm_group_label>ALXN1830 Dosing Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of myasthenia gravis.&#xD;
&#xD;
          -  Positive serologic test for anti-acetylcholine receptor antibodies.&#xD;
&#xD;
          -  Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at&#xD;
             Screening.&#xD;
&#xD;
          -  MG-ADL profile must be ≥ 5.&#xD;
&#xD;
          -  Participants receiving stable treatment with azathioprine; other immunosuppressive&#xD;
             therapies.&#xD;
&#xD;
          -  Total IgG level at Screening ≥ 600 milligrams/deciliter.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of thymectomy, thymomectomy, or any other thymic surgery within 12 months&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Any untreated thymic malignancy, carcinoma, or thymoma.&#xD;
&#xD;
          -  Intravenous immunoglobulin within the 6 weeks, and/or use of plasmapheresis/plasma&#xD;
             exchange prior to randomization (Day 1).&#xD;
&#xD;
          -  Use of rituximab within the 3 months (90 days) prior to Screening.&#xD;
&#xD;
          -  Participants who have received previous treatment with any biological agent or other&#xD;
             anti-neonatal fragment crystallizable receptor therapy within 5 half-lives or 90 days&#xD;
             after last dose (whichever is longer).&#xD;
&#xD;
          -  Known medical or psychological condition(s) or risk factor that, in the opinion of the&#xD;
             Investigator, might interfere with the participant's full participation in the study,&#xD;
             pose any additional risk for the participant, or confound the assessment of the&#xD;
             participant or outcome of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Generalized Myasthenia Gravis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

